From Today's $tockhead PYC’s drug shows promise in eye disease...

From Today's $tockhead
PYC’s drug shows promise in eye disease trials

PYC Therapeutics (ASXYC) has provided an update on its ongoing clinical trials for VP-001, an investigational drug candidate designed to treat Retinitis Pigmentosa type 11 (RP11).
RP11 is a rare and severe eye disease that leads to blindness.
The company has previously highlighted encouraging developments in its trials, showcasing the drug’s potential to significantly improve visual function in affected patients.
In its latest update, PYC revealed that VP-001 has continued to show positive effects in patients from the Single Ascending Dose (SAD) study.
The drug was initially administered to a patient, and two months later, this individual showed notable improvements in visual function.
This improvement has been sustained, with further positive results observed four months after treatment.
A second patient in the same cohort has also demonstrated similar progress, with their visual function improving to levels deemed clinically significant by the US FDA.
PYC is also advancing with its Multiple Ascending Dose (MAD) study, where initial dosing in the first cohort was completed in July.
Patients in this study will continue to be monitored, with the next group of patients scheduled to receive their doses in the coming months.
The first patient in the SAD study’s extension phase has received a second dose, marking the start of a regimen involving multiple doses of VP-001.
“It is exciting to see VP-001’s ability to address the root cause of RP11 in ‘retina in a dish’ models now translating to improved visual function in RP11 patients,” said PYC’s CEO, Dr. Rohan Hockings.
The company’s near-term goal is to establish clinical proof of concept through these trials.
Successful outcomes could lead to the initiation of a registrational study aimed at securing regulatory approval and launching the drug in the market.
Looking ahead, PYC will continue to gather data from ongoing trials, including both single and multiple dose studies, with the aim of providing further evidence of the drug’s efficacy.